ABOUT US
We are a Danish medical technology company aiming to transform the diagnosis of genetic disorders for better disease management.
The gMendel® approach
is powered by genomics, AI and blockchain technology.
Our mission is to provide a shorter, safer and economical path to accurate diagnosis of genetic disorders and potential treatment.
Genotyping
We have developed a proprietary method for high-throughput and cost-effective genotyping. By calculating fractions of reads, our diagnostic tool can identify gene mutations and chromosomal aberrations from a normal karyotype and hence recognize genetic disorders.
AI
We harness the full power of analytics and Artificial Intelligence throughout the complete sequencing process. By using machine learning algorithms, our proprietary technology translates real-time data into accurate and meaningful results.
Blockchain
We use private blockchains to ensure highest security and patient data encryption. The use of blockchain technology in healthcare applications offers unique privacy and security advantages, as it is decentralized, incorruptible and transparent.
At gMendel®, we want to make sure that all our products, services and processes meet our customers’ needs. This is why we have defined a robust quality management system (QMS) and a risk management process, conforming to ISO 13485 and ISO 14971, respectively.
Download our ISO certification
Our Story
gMENDEL WAS INSPIRED BY THE PERSONAL STORIES OF THE TWO FOUNDERS, CHRIS AND ZORAN.
In 2016, Chris’s 4-year-old daughter, Ilma, was diagnosed with selective mutism. The diagnosis forced Chris and his family to slow down and reflect on what was important in life. It was then when Chris decided to take a 10-month parental leave to give his daughter the time and attention she needed to thrive. With the strong support of her family, Ilma made tremendous progress and is now taking part in all learning and social activities at her school.
Some years ago, Zoran received the news that his childhood friend suffered from a rare cancer type. The exact diagnosis was only possible after DNA sequencing. While going through the complicated journey of healthcare, Zoran realized that although DNA sequencing had been a long-available technology, it was only accessible to few, due to its high cost.
Their ambition to involve DNA sequencing in routine clinical practice, led Chris and Zoran to the foundation of gMendel® in 2020.
They committed to developing a smart technology that could provide early, accurate and affordable diagnosis of genetic disorders to all heroes out there living with rare diseases.
At gMendel® we think big, start small and act now.
7 years horizon
2020 – Q1 2021
In 2019, we developed a fast (<24h), cost-effective method for bacterial DNA enrichment and tagmentation in the lab, allowing species identification and strain differentiation.
We partnered up with leading research teams and data scientists for further development and support in human genomes.
Q2 2021 – Q2 2022
Version 1.0.0 of our Phivea® is released under the 98/79/EC IVD Directive in Q1 2022.
After registration and approval from the Danish regulatory authorities in May 2022, we will continue registration and approval in more EU markets such as Poland, Spain and Greece. Next, we plan to start pilot projects within private/public hospitals and private diagnostic centres in order to collect more data and invaluable customer input for our future products.
Q3 2022 – Q4 2024
a) Basic Carrier Test (BCT) for future parents (before conception)
b) Non-Invasive Prenatal Test (NIPT) (during pregnancy)
c) Newborn Screening Test (NBS) (after birth).
We aim to include the gMendel®Test in national healthcare protocols for prenatal and postnatal diagnosis, creating synergies with pharmaceutical companies to stimulate research and development in orphan drugs, and facilitating collaboration and constructive dialogue with national health policy bodies and platforms.
Q1 2025 – Q4 2027
a) Epigenetics
b) Neurological Genetic Disorders
c) Graft vs. Host Disease
d) Whole Genome Sequencing via Targeted Sequencing.
Meet the team
Chris Kyriakidis
PhD, MSc, MBA | Co-founder
Zoran Velkoski
MSc, MBA | Co-founder
Aleksandar Nikov
BSc | Head of AI
Robert Burger
PhD, Dipl. Ing, MBA | Head of Product
Kristijan Jankoski
MSc | Senior Data Scientist
David Galevski
MSc | Data Scientist
Anne Schack
MSc | Genomics Researcher
Thomasz Puk *
MSc, MBA | Head of Q&R
Jarosław Kowalczyk *
MSc | Quality Assurance Manager
Dimitris Kyriakidis
MSc | Advocacy & Sales Development - Spain, Portugal, Italy & Greece
Maria Andrielou *
MSc, MA | Head of Marketing & Communication
Dariusz Nabiałczyk *
MSc | Software Architect
Agnieszka Tymoszyk *
BSc | QA Engineer
Marija Chaushevska
MSc | AL/ML Researcher
Karmele Alapont Celaya
MSc | Genomics Researcher
Wouter Hamelink *
MSc | Advocacy & Sales Development - Netherlands & Belgium
Carmen Garrido Navas*
Ph.D., MSc | Head of Genetics and Clinical Investigator
Theofania Tsitsopoulou
BSc | Research Intern
Advisors
Zoran Zdraveski
J.D., Ph.D. | Strategic Advisor
Gjorgji Madjarov *
Ph.D., MSc | AI Advisor
Lukasz Krych *
Ph.D., MSc | Genomics Advisor
Johan Leonhard *
LLM, Attorney | Legal Advisor
Ken Ndugga-Kabuye *
Ph.D. | US Market Advisor
Board of Directors
Lars Staal Wegner
M.D. | Chairman of the BoD
Hanna Pyokari
MSc. | Member of the BoD
*Gjorgji: Professor at the Ss Cyril & Methodius University of Skopje
Lukasz: Associate Professor at the University of Copenhagen
Tomasz, Jarosław, Dariusz, Agnieszka: Members of the Star.Global Team
Maria: Clean Stories
María del Carmen: GENyO. Pfizer-University of Granada-Junta de Andalucia Center for Genomics and Oncological Research
Johan: Partner at Nyborg & Rørdam Law firm P/S